Background: Monoclonal antibodies are nowadays by far the most important of all biotherapeutics. Unfortunately, they are complex proteins, so that their production is complicated and expensive, which eventually leads to an elevated average cost per treatment per patient. An important research effort is dedicated to the development of a process that may allow a reduction of antibodies production costs.
No takes yet. Share an insight, caveat, or question.
Boi et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: